CRISPR updates early-stage trial knowledge for coronary heart illness drug

CRISPR Therapeutics (CRSP) on Saturday introduced new outcomes from a Part 1 trial for CTX310, an in vivo gene enhancing remedy for sufferers with excessive ranges of triglycerides and low-density lipoprotein (LDL) ldl cholesterol, also referred to as “unhealthy” ldl cholesterol.

After a